+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Viral Vector & Plasmid DNA Manufacturing Market Analysis Report By Application, By Disease (Cancer, Genetic), By Workflow (Upstream, Downstream), By Vector, By End Use, And Segment Forecasts, 2019 - 2025

  • ID: 4751750
  • Report
  • 170 pages
  • Grand View Research
1 of 3

FEATURED COMPANIES

  • Brammer Bio
  • Cobra Biologics Ltd.
  • Genezen
  • Lonza
  • Merck KGaA
  • Regenxbio, Inc.
  • MORE
The global viral vector & plasmid DNA manufacturing market size is expected to reach USD 882.9 million by 2025, rising at a 16.0% CAGR during the forecast period. Rising number of gene therapy-based discovery programs in the pharma industry is one of the key trends driving the production of gene therapy vectors. Moreover, a robust pipeline of viral vaccines and gene therapies has prompted companies to develop novel and effective technologies for scalable manufacturing of vectors. Current vector manufacturing process is considered highly regulated, elaborate, and expensive.

Moreover, at present, there is a shortage of production sites to meet the demand by the pharmaceutical industry for vector construction services. These factors have created opportunities for companies to capitalize on potential avenues in the market through developing novel solutions.

Key growth strategies adopted by companies to sustain their market presence include continuous expansion of manufacturing sites in high-demand markets such as the U.S. and U.K. Moreover, companies are engaged in strategic mergers & facility acquisitions to meet growing requirements of viral vectors within the pharmaceutical and biotech industries and to broaden their service portfolios.

Further Key Findings From the Report Suggest:
  • Adenovirus and retrovirus were prominent vector type segments in the market in 2017. These can be produced at high titers and induce a strong humoral and, especially, a strong T cell response, as a result of which these vector type is extensively employed in vaccines
  • Lentiviral production costs nearly up to 40.0% of the total cost of goods, thus inducing revenue growth in this vector type
  • Downstream processing accounted for the largest share in 2017, owing to requirement of expensive equipment and skilled personnel for product recovery
  • In terms of application, vector manufacturing for antisense, RNAi, & molecular therapy production represented the leading revenue share in 2017. This is due to high adoption rate of viruses for oligonucleotide and aptamers development in comparison to other applications
  • The number of biotech companies that are engaged in employing vector for therapeutic production continue to increase over the period
  • Recent approval of cancer gene therapy products encourages further efforts in this arena, thus resulting in the cancer segment holding the dominant revenue share
  • North America led the global market owing to presence of several universities and research institutes that are engaged in genomic research programs
  • Cobra Biologics, Merck, uniQure N.V., and Novasep are some key participants that are focusing towards capitalizing of untapped avenues in the market.

Please note: This product will be delivered within 48 business hours after receipt of order.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Brammer Bio
  • Cobra Biologics Ltd.
  • Genezen
  • Lonza
  • Merck KGaA
  • Regenxbio, Inc.
  • MORE
Chapter 1 Executive Summary
1.1 Market Snapshot

Chapter 2 Research Methodology
2.1 Information Procurement
2.1.1 Purchased Database
2.1.2 Internal database
2.2 Data Analysis
2.3 Market Formulation & Validation
2.4 Approaches for Market Estimation
2.4.1 Approach 1: Commodity Flow & Bottom Up Approach
2.4.2 Approach 2: Top Down and Parent Market Analysis

Chapter 3 Viral Vector & Plasmid DNA Manufacturing Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.1.1 Market driver analysis
3.1.1.1 Robust pipeline for gene therapies and viral vector vaccines
3.1.1.2 Technological advancements for vector production
3.1.1.3 Highly competitive market and various marketing strategies undertaken by the operating entities
3.1.2 Market restraint analysis
3.1.2.1 Regulatory, scientific, and ethical challenges associated with gene therapy
3.1.3 Challenge analysis
3.1.3.1 Production capacity challenges
3.1.3.2 Manufacturing challenges pertaining to the production of vector at large scale
3.1.4 Opportunity analysis
3.1.4.1 Facility expansion for cell and gene therapies
3.1.4.2 Investments, collaboration & partnerships in cell and gene therapies space
3.2 Penetration & Growth Prospect Mapping For Vector Type, 2017
3.3 Viral Vector & Plasmid DNA Manufacturing Market-Swot Analysis, By Factor (Political & Legal, Economic And Technological)
3.4 Industry Analysis - Porter’s

Chapter 4 Viral Vector & Plasmid DNA Manufacturing Market Categorization: Vector Type Estimates & Trend Analysis
4.1 Viral Vector & Plasmid DNA Manufacturing Market: Vector Type Movement Analysis
4.2 Adenovirus
4.2.1 Global adenovirus market, 2014 - 2025 (USD Million)
4.3 Retrovirus
4.3.1 Global retrovirus market, 2014 - 2025 (USD Million)
4.4 Plasmid DNA
4.4.1 Global plasmid DNA market, 2014 - 2025 (USD Million)
4.5 AAV
4.5.1 Global AAV market, 2014 - 2025 (USD Million)
4.6 Lentivirus
4.6.1 Global lentivirus market, 2014 - 2025 (USD Million)
4.7 Other Vectors
4.7.1 Global other vectors market, 2014 - 2025 (USD Million)

Chapter 5 Viral Vector & Plasmid DNA Manufacturing Market Categorization: Workflow Estimates & Trend Analysis
5.1 Viral Vector & Plasmid DNA Manufacturing Market: Workflow Movement Analysis
5.2 Upstream Manufacturing
5.2.1 Global upstream manufacturing market, 2014 - 2025 (USD Million)
5.2.2 Vector amplification & expansion
5.2.2.1 Global vector amplification & expansion market, 2014 - 2025 (USD Million)
5.2.3 Vector recovery/harvesting
5.2.3.1 Global vector recovery/harvesting market, 2014 - 2025 (USD Million)
5.3 Downstream Manufacturing
5.3.1 Global downstream manufacturing market, 2014 - 2025 (USD Million)
5.3.2 Purification
5.3.2.1 Global purification market, 2014 - 2025 (USD Million)
5.3.3 Fill-finish
5.3.3.1 Global fill-finish market, 2014 - 2025 (USD Million)

Chapter 6 Viral Vector & Plasmid DNA Manufacturing Market Categorization: Application Estimates & Trend Analysis
6.1 Viral Vector & Plasmid DNA Manufacturing Market: Application Movement Analysis
6.2 Antisense, RNAi, & Molecular Therapy
6.2.1 Market for antisense, RNAi, & molecular therapy, 2014 - 2025 (USD Million)
6.3 Vaccinology
6.3.1 Market for vaccinology, 2014 - 2025 (USD Million)

Chapter 7 Viral Vector & Plasmid DNA Manufacturing Market Categorization: End-use Estimates & Trend Analysis
7.1 Viral Vector & Plasmid DNA Manufacturing Market: End-use Movement Analysis
7.2 Pharmaceutical and Biopharmaceutical Companies
7.2.1 Market for pharmaceutical and biopharmaceutical companies, 2014 - 2025 (USD Million)
7.3 Research Institutes
7.3.1 Market for research institutes, 2014 - 2025 (USD Million)

Chapter 8 Viral Vector & Plasmid DNA Manufacturing Market Categorization: Disease Estimates & Trend Analysis
8.1 Viral Vector & Plasmid DNA Manufacturing Market: Disease Movement Analysis
8.2 Cancer
8.2.1 Market for cancer, 2014 - 2025 (USD Million)
8.3 Genetic disorders
8.3.1 Market for genetic disorders, 2014 - 2025 (USD Million)
8.4 Infectious diseases
8.4.1 Market for infectious diseases, 2014 - 2025 (USD Million)
8.5 Others
8.5.1 Market for other diseases, 2014 - 2025 (USD Million)

Chapter 9 Viral Vector & Plasmid DNA Manufacturing Market Categorization: Regional Estimates & Trend Analysis
9.1 Viral Vector & Plasmid DNA Manufacturing Market Share By Regional, 2017 & 2025
9.2 North America
9.2.1 Market, 2014 - 2025 (USD Million)
9.2.2 U.S.
9.2.2.1 Market, by vector type, 2014 - 2025 (USD Million)
9.2.2.2 Market, by workflow, 2014 - 2025 (USD Million)
9.2.2.3 Market, by application, 2014 - 2025 (USD Million)
9.2.2.4 Market, by end-use, 2014 - 2025 (USD Million)
9.2.2.5 Market, by disease, 2014 - 2025 (USD Million)
9.2.3 Canada
9.2.3.1 Market, by vector type, 2014 - 2025 (USD Million)
9.2.3.2 Market, by workflow, 2014 - 2025 (USD Million)
9.2.3.3 Market, by application, 2014 - 2025 (USD Million)
9.2.3.4 Market, by end-use, 2014 - 2025 (USD Million)
9.2.3.5 Market, by disease, 2014 - 2025 (USD Million)
9.3 Europe
9.3.1 Market, 2014 - 2025 (USD Million)
9.3.2 Germany
9.3.2.1 Market, by vector type, 2014 - 2025 (USD Million)
9.3.2.2 Market, by workflow, 2014 - 2025 (USD Million)
9.3.2.3 Market, by application, 2014 - 2025 (USD Million)
9.3.2.4 Market, by end-use, 2014 - 2025 (USD Million)
9.3.2.5 Market, by disease, 2014 - 2025 (USD Million)
9.3.3 U.K.
9.3.3.1 Market, by vector type, 2014 - 2025 (USD Million)
9.3.3.2 Market, by workflow, 2014 - 2025 (USD Million)
9.3.3.3 Market, by application, 2014 - 2025 (USD Million)
9.3.3.4 Market, by end-use, 2014 - 2025 (USD Million)
9.3.3.5 Market, by disease, 2014 - 2025 (USD Million)
9.4 Asia Pacific
9.4.1 Market, 2014 - 2025 (USD Million)
9.4.2 Japan
9.4.2.1 Market, by vector type, 2014 - 2025 (USD Million)
9.4.2.2 Market, by workflow, 2014 - 2025 (USD Million)
9.4.2.3 Market, by application, 2014 - 2025 (USD Million)
9.4.2.4 Market, by end-use, 2014 - 2025 (USD Million)
9.4.2.5 Market, by disease, 2014 - 2025 (USD Million)
9.4.3 China
9.4.3.1 Market, by vector type, 2014 - 2025 (USD Million)
9.4.3.2 Market, by workflow, 2014 - 2025 (USD Million)
9.4.3.3 Market, by application, 2014 - 2025 (USD Million)
9.4.3.4 Market, by end-use, 2014 - 2025 (USD Million)
9.4.3.5 Market, by disease, 2014 - 2025 (USD Million)
9.5 Latin America
9.5.1 Market, 2014 - 2025 (USD Million)
9.5.2 Brazil
9.5.2.1 Market, by vector type, 2014 - 2025 (USD Million)
9.5.2.2 Market, by workflow, 2014 - 2025 (USD Million)
9.5.2.3 Market, by application, 2014 - 2025 (USD Million)
9.5.2.4 Market, by end-use, 2014 - 2025 (USD Million)
9.5.2.5 Market, by disease, 2014 - 2025 (USD Million)
9.6 MEA
9.6.1 Market, 2014 - 2025 (USD Million)
9.6.2 South Africa
9.6.2.1 Market, by vector type, 2014 - 2025 (USD Million)
9.6.2.2 Market, by workflow, 2014 - 2025 (USD Million)
9.6.2.3 Market, by application, 2014 - 2025 (USD Million)
9.6.2.4 Market, by end-use, 2014 - 2025 (USD Million)
9.6.2.5 Market, by disease, 2014 - 2025 (USD Million)

Chapter 10 Competitive Landscape
10.1 List of Companies With Portfolio for Vector-based Therapeutic Candidate
10.2 List of Vector Manufacturers
10.3 Strategy Framework
10.4 Market Participation Categorization
10.5 Company Profiles
10.5.1 Merck KGaA
10.5.1.1 Company overview
10.5.1.1.1 Sigma-Aldrich Co. LLC
10.5.1.2 Financial performance
10.5.1.3 Product benchmarking
10.5.1.4 Strategic initiatives
10.5.2 Lonza
10.5.2.1 Company overview
10.5.2.2 Financial performance
10.5.2.3 Product benchmarking
10.5.2.4 Strategic initiatives
10.5.3 FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
10.5.3.1 Company overview
10.5.3.2 Financial performance
10.5.3.3 Product benchmarking
10.5.3.4 Strategic initiatives
10.5.4 Cobra Biologics Ltd.
10.5.4.1 Company overview
10.5.4.2 Financial performance
10.5.4.3 Product benchmarking
10.5.4.4 Strategic initiatives
10.5.5 Brammer Bio
10.5.5.1 Company overview
10.5.5.2 Financial performance
10.5.5.3 Product benchmarking
10.5.5.4 Strategic initiatives
10.5.6 Waisman Biomanufacturing
10.5.6.1 Company overview
10.5.6.2 Financial performance
10.5.6.3 Product benchmarking
10.5.6.4 Strategic initiatives
10.5.7 Genezen
10.5.7.1 Company overview
10.5.7.2 Financial performance
10.5.7.3 Product benchmarking
10.5.7.4 Strategic initiatives
10.5.8 YPOSKESI
10.5.8.1 Company overview
10.5.8.2 Financial performance
10.5.8.3 Product benchmarking
10.5.8.4 Strategic initiatives
10.5.9 REGENXBIO, Inc.
10.5.9.1 Company overview
10.5.9.2 Financial performance
10.5.9.3 Product benchmarking
10.5.9.4 Strategic initiatives
10.5.10 Cell and Gene Therapy Catapult
10.5.10.1 Company overview
10.5.10.2 Financial performance
10.5.10.3 Product benchmarking
10.5.10.4 Strategic initiatives
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Merck KGaA
  • Lonza
  • FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
  • Cobra Biologics Ltd.
  • Brammer Bio
  • Waisman Biomanufacturing
  • Genezen
  • Yposkesi
  • Regenxbio, Inc.
  • Cell and Gene Therapy Catapult
Note: Product cover images may vary from those shown
Adroll
adroll